SQ2 | Jotup

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference

Retrieved on:

Monday, June 19, 2023

Andrew Charrette, Director Regulatory Affairs, KGK Science Inc., will participate on the “Decomposing Regulatory Risk: How to Develop and Market Compliant and Impactful Myco Products” panel at 2:30pm MDT on June 20th.

Key Points:

Andrew Charrette, Director Regulatory Affairs, KGK Science Inc., will participate on the “Decomposing Regulatory Risk: How to Develop and Market Compliant and Impactful Myco Products” panel at 2:30pm MDT on June 20th.
Psychedelic Science 2023 is the premier opportunity to reach a passionate audience over five days in Denver at the largest psychedelic community gathering in history.
Najla Guthrie, CEO of KGK & Wellbeing will participate on two panels:
Elephant in the Room?
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at [email protected] .

Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group

Retrieved on:

Friday, June 16, 2023

Biotechnology, Health, Mental Health, Agreement, Shareholder, Therapy, Asset purchase agreement, Meeting, FRA, MEDI, KGK, Sales management, Acquisition, Transaction, OTC, SQ2, NEO, Security (finance)

In consideration for the acquisition of KGK, the Purchaser has agreed to pay $2,000,000 (the “Purchase Price”), from which they advanced a non-refundable deposit of $200,000 upon signing of the Purchase Agreement.

Key Points:

In consideration for the acquisition of KGK, the Purchaser has agreed to pay $2,000,000 (the “Purchase Price”), from which they advanced a non-refundable deposit of $200,000 upon signing of the Purchase Agreement.
Further deposits can be advanced at the discretion of the Purchaser, subject to the approval of the Company, prior to completion of the Transaction.
The Company and KGK are at arms-length from the Purchaser, and no finders’ fees or commissions are payable by the Company in connection with the entering into of the Purchase Agreement.
During the period between the signing of the Agreement and the closing of the Transaction, Wellbeing will continue to operate the business in accordance with customary interim operating covenants.

Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference

Retrieved on:

Thursday, May 25, 2023

Mental Health, Health, Fitness & Nutrition, Research, Science, Pharmaceutical, Biotechnology, MEDI, KGK, Therapy, SQ2, NEO, FRA, OTC

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary KGK Science Inc. (“KGK” or the “Subsidiary”) will participate at the upcoming Nutrition Industry Association (“NIA”) Spring Forum to take place on May 29 to June 1, 2023 in California.

Key Points:

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary KGK Science Inc. (“KGK” or the “Subsidiary”) will participate at the upcoming Nutrition Industry Association (“NIA”) Spring Forum to take place on May 29 to June 1, 2023 in California.
Najla Guthrie will participate on the “From functional food to prescription medication, mushrooms are the center of the conversation” panel at 11:00 AM PST on Tuesday May 30th.
Industry professionals will gather once again for the Nutrition Industry Association’s annual Spring meeting.
For more information about the conference, or to schedule a one-on-one meeting with the KGK management team, please send an email to Natalie Dolphin at [email protected] .

Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response

Retrieved on:

Wednesday, May 3, 2023

The resultant proprietary blend of these botanical ingredients in UP360 produces antioxidant, anti-inflammatory, and immunomodulatory effects.

Key Points:

The resultant proprietary blend of these botanical ingredients in UP360 produces antioxidant, anti-inflammatory, and immunomodulatory effects.
This is the first study to examine a proprietary combination of these ingredients using a human vaccine model.
The randomized, triple-blind, placebo-controlled clinical trial involving supplementation with UP360 provides evidence for a robust, healthy immune response in adults following influenza vaccination.
“UP360 supplementation provided a beneficial immune defense response and improved antioxidant function in conjunction with traditional vaccination, adopted by many as part of their overall immune health strategy,” says Dr. Corey Hilmas, Chief Scientific Affairs and Regulatory Officer at KGK Science.

Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial

Retrieved on:

Tuesday, April 18, 2023

The 28-day study will test the safety and efficacy of Nova Mentis’ proprietary psilocybin drug (NM-1001) for the treatment of FXS and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day.

Key Points:

The 28-day study will test the safety and efficacy of Nova Mentis’ proprietary psilocybin drug (NM-1001) for the treatment of FXS and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day.
Nova Mentis and KGK have partnered to conduct the Phase IIA clinical trial, which is being carried out at the KGK facility in London, Ontario, Canada.
This 10-person, open-label study will assess repetitive, oral microdose psilocybin therapy for FXS.
“KGK Science is eager to begin testing the efficacy of microdosing psilocybin in this cutting-edge clinical trial.

Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval

Retrieved on:

Tuesday, April 11, 2023

“KGK Science is thrilled to have received all of the regulatory approvals required to conduct this cutting-edge clinical trial.

Key Points:

“KGK Science is thrilled to have received all of the regulatory approvals required to conduct this cutting-edge clinical trial.
We believe the first-ever Phase IIA clinical trial will be an impactful assessment of the potential of psilocybin in a disorder that truly affects the lives of many families and that has not yet been studies,” commented Najla Guthrie, CEO of Wellbeing and KGK.
The trial will be led by KGK Science and recruiting efforts are expected to begin this year.
“This approval further validates our high standards of ethical and clinical practice and is a significant clinical milestone for this study.”

Wellbeing Announces Cease Trade Order

Retrieved on:

Thursday, April 6, 2023

The Company is working diligently and expeditiously with its auditors and expects to file the Documents as soon as possible with a current expectation of on or about April 30, 2023.

Key Points:

The Company is working diligently and expeditiously with its auditors and expects to file the Documents as soon as possible with a current expectation of on or about April 30, 2023.
There is no assurance that the Company will be able to remedy its filing default and have the FFCTO lifted in a timely manner or at all.
The forward-looking statements contained in this news release are made as of the date of this news release.
Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Wellbeing Provides Bi-Weekly Default Status Report

Retrieved on:

Thursday, March 16, 2023

The Company is providing this status update in accordance with National Policy 12-203 Management Cease Trade Orders ("NP 12-203").

Key Points:

The Company is providing this status update in accordance with National Policy 12-203 Management Cease Trade Orders ("NP 12-203").
The Company intends to follow the provisions of the Alternative Information Guidelines under NP 12-203, by issuing bi-weekly default status reports in the form of news releases so long as the Company remains in default.
The forward-looking statements contained in this news release are made as of the date of this news release.
Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference

Retrieved on:

Thursday, March 16, 2023

Research, Mental Health, Finance, Professional Services, Small Business, Biotechnology, Alternative Medicine, General Health, Health, Science, Conference, FRA, EST, SQ2, NEO, Therapy, OTC, MEDI, Nightclub

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at the upcoming Benzinga Psychedelic Capital Conference taking place on April 13th, 2023 in Miami Florida.

Key Points:

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at the upcoming Benzinga Psychedelic Capital Conference taking place on April 13th, 2023 in Miami Florida.
The Benzinga Psychedelics Capital Conference educates and informs the current and future psychedelics investor on the state of the industry, cutting-edge developments, and provides opportunities for curated networking and unparalleled access to private deal flow.
Najla Guthrie will participate on the “Psychedelics 101” panel at 9:50 a.m. EST on April 13th, 2023.
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at [email protected] .

Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion

Retrieved on:

Monday, March 13, 2023

Mental Health, Clinical Trials, Health Technology, Telemedicine, Virtual Medicine, Biotechnology, Alternative Medicine, Health, Pharmaceutical, General Health, OTC, NEO, MEDI, Therapy, SQ2, FRA, Pharmaceutical industry

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate virtually at the upcoming Cantor Fitzgerald Psychedelic Clinics panel discussion on March 15, 2023.

Key Points:

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate virtually at the upcoming Cantor Fitzgerald Psychedelic Clinics panel discussion on March 15, 2023.
Najla Guthrie will participate on the “Weednesday with Pablo Series- Psychedelics Clinics” panel at 11:00 AM Eastern Time.
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at [email protected] .